Huntington Disease

Huntington disease is a fatal inherited brain disorder causing movement, cognitive and psychiatric decline; most gene-positive carriers remain undiagnosed for years before any clinical sign appears.

About Huntington Disease

In numbers

Huntington disease affects an estimated 4.88 people per 100,000 globally, with around 44,000 people diagnosed in the USA and 37,000 across the EU4 and UK.
Between 150,000 and 200,000 people in the USA are gene-positive but pre-manifest, meaning they carry no diagnostic code and show no clinical signs yet.
The pre-manifest population is estimated at three to five times the size of the diagnosed population, making it the largest addressable group in the disease.

Special details

Prevalence is highest in people of European ancestry, at around 7 to 10 per 100,000, reflecting founder effects in specific genetic backgrounds.
Prevalence is lower in Asian and Sub-Saharan African populations, at around 1 to 4 per 100,000, reflecting different underlying genetic architecture.
Onset is most common between the ages of 35 and 44, though 5 to 10 percent of cases begin before age 21 as juvenile-onset disease.

Signs and symptoms of Huntington Disease

Diagnosis typically takes 1.8 to 3 years from symptom onset in people with a known family history, and can take five years or more where family history is absent or symptoms are atypical.

Psychiatric prodrome

Depression, irritability, anxiety and apathy can appear 10 to 15 years before any motor diagnosis.

Cognitive slowing

Processing speed and executive function decline early, often detected only on formal testing.

Chorea

Involuntary, flowing movements affect around 90 percent of adult-onset patients at some stage.

Dysphagia

Swallowing difficulty affects most patients by mid to late stage and drives most complications.

Progressive dependence

Advanced disease brings loss of speech and movement, with aspiration pneumonia the leading cause of death.

Key challenges from product development to launch

Strategy and Business

The wrong disease or indication selected for investment
Indications tackled in the wrong order due to shaky success estimates
R&D returns slipping below the cost of capital

Clinical Development

Trials delayed by low patient recruitment
High screen-failure rates that raise trial cost
Mixed cohorts that make the signals difficult to detect

HEOR, Access & Value

A value case that arrives too late or is underdeveloped
Eligible population under-counted, budget-impact case unsubstantiated
Approved by the regulator, delayed at HTA

Medical Affairs

Fragmented, differently-coded healthcare data
Diagnostic delay that is long and unequal
No shared evidence base across functions

Launch and Commercial

Launch planned without a view of the number of findable patients
Targeting too broad a population slows early uptake
RWE started too late to build the case

How Volv Global Helps

Strategy and Business

The earliest pipeline decisions carry lasting consequences: the wrong indication chosen, indications pursued in the wrong order, or capital committed where expected returns already trail its cost. Mistakes made this early are expensive to correct later.

inTrigue

Finds the true reachable population per candidate, so indication choices rest on evidence.

volv.global/finding-patients

inFlow

Adds probability-of-success and outcome evidence to help prioritise the pipeline.

volv.global/predict-patient-outcomes

Clinical Development

When patients cannot be found, recruitment stalls and the burn rate climbs. High screen-failure rates add further cost and delay, and a mixed cohort makes the results harder to interpret.

inTrigue

Finds the undiagnosed and mis-coded patients conventional feasibility misses, widening the recruitable pool.

volv.global/finding-patients

inCare

Surfaces diagnosed-but-hidden, trial-eligible patients already in the data, so sites enrol faster.

volv.global/stratifying-patient-cohorts

inFlow

Predicts who will progress or respond, enriching the cohort so the signal is not diluted.

volv.global/predict-patient-outcomes

HEOR, Access & Value

Without strong, timely evidence, payers can restrict access or cut the price. An under-characterised population weakens the budget case, and HTA approval demands more evidence than regulatory approval alone.

inFlow

Generates the real-world evidence and outcomes payers ask for, ahead of the submission deadline.

volv.global/predict-patient-outcomes

inTrigue

Finds the undiagnosed patients missing from the count, so the eligible population holds up under scrutiny.

volv.global/finding-patients

inCare

Surfaces the diagnosed-but-eligible patients who expand the eligible population count.

volv.global/stratifying-patient-cohorts

Medical Affairs

Healthcare data is fragmented across markets, so evidence has to be rebuilt market by market, slowing decisions. Time to an accurate diagnosis varies by who the patient is and where they are treated.

inTrigue

Works across fragmented, differently-coded data by design, so insight holds up country to country without a rebuild.

volv.global/finding-patients

inAdvance

Detects patients ahead of typical diagnosis, closing the gap in awareness and pathway that drives unequal delay.

volv.global/earlier-detection

Launch and Commercial

A launch planned without a view of findable patients is poorly resourced from day one. Targeting too broad a population slows early uptake, and real-world evidence gathered too late leaves little time to build a strong access dossier.